HR-7173-119
Referred to the House Committee on Energy and Commerce.
Sponsored by Diana DeGette (D-CO)
What it does
This bill would amend the Public Health Service Act to bar most political appointees from being employed by or participating in the management of the National Institutes of Health (NIH), with narrow exceptions for the NIH Director, the National Cancer Institute Director, and the ARPA-H Director. It would also prohibit political appointees from participating in the solicitation, review, scoring, or awarding of NIH grants and contracts. Additionally, it would bar NIH from canceling, delaying, or suspending any active grant or contract unless written findings of financial mismanagement, research fraud, debarment, or malfeasance are issued and reported to Congress within 30 days.
Who benefits
Researchers and academic institutions currently holding or seeking NIH grants, who would gain protection against politically motivated cancellations. Universities and research hospitals dependent on NIH funding. Career NIH scientists and staff whose peer-review processes would be insulated from political appointee interference. Patients and the public who benefit from NIH-funded research continuity. Biomedical and pharmaceutical companies that rely on NIH-funded basic research as a pipeline for drug development.
Who is hurt
The executive branch — particularly the sitting President and HHS Secretary — would lose discretionary authority to direct NIH priorities, cancel grants, or place political appointees in NIH roles. Future administrations of either party would face statutory constraints on managing NIH. Taxpayers who believe certain NIH-funded research is wasteful or misaligned with public priorities would have fewer political levers to redirect spending. Whistleblowers or oversight actors seeking to halt a specific grant on policy grounds (short of fraud or malfeasance) would face a higher legal bar.
Supporters argue
Supporters argue that NIH's $47 billion annual budget funds peer-reviewed science that depends on insulation from political interference to produce reliable results, and that recent grant cancellations by political appointees — without findings of fraud or mismanagement — have disrupted ongoing research and damaged the U.S. scientific enterprise. They contend that the bill codifies longstanding norms: career scientists, not political appointees, have always conducted peer review, and that requiring written findings before cancellation simply holds NIH to the same accountability standards applied to other federal contracts under the Federal Acquisition Regulation.
Opponents argue
Opponents argue that the President, as head of the executive branch, has constitutional authority to direct federal agencies and set research priorities, and that this bill unconstitutionally constrains that authority by stripping political appointees — who are accountable to elected officials — from meaningful oversight of a $47 billion agency. They contend that the grant-cancellation prohibition effectively converts discretionary federal spending into near-permanent entitlements for grantees, removing the executive's ability to redirect funds toward higher-priority research without meeting a judicially reviewable fraud standard, and that Congress cannot legislate away the President's core Article II supervisory powers.
Constitutional context
The bill implicates the separation of powers and the President's Article II authority to supervise executive branch agencies. While Congress has broad authority under the Taxing and Spending Clause (Art. I, §8, cl. 1) to attach conditions to federal spending, restrictions that effectively strip the President of supervisory control over executive officers may conflict with the Appointments Clause and the Take Care Clause. Post-Loper Bright (2024), courts would independently assess whether statutory language sufficiently authorizes or limits agency action, without deferring to executive interpretations.
Checks and balances
Congress would gain oversight authority — NIH must report grant cancellations to two committees within 30 days — while the executive branch (President, HHS Secretary, and political appointees) would lose discretionary authority over NIH staffing and grant management; judicial review of cancellation decisions would become more accessible to grantees.
Historical precedent
The Hatch Act (1939) and subsequent civil service laws have long restricted political activity by federal employees, but no prior statute has specifically barred political appointees from NIH grant management or prohibited grant cancellations without written findings of misconduct.